- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
New Study Shows High Effectiveness of Misoprostol-Only in medical Abortion Regimens
A recent study has shed light on the high effectiveness of misoprostol-alone regimens for self-managed abortion, challenging previous assumptions. The study found that misoprostol alone can effectively terminate the pregnancy of <7 weeks duration in 24 hours.
The study results were published in JAMA Network Open.
The World Health Organization recommends two medication regimens for abortion: mifepristone combined with misoprostol and misoprostol alone. Both are effective with low complication rates. Misoprostol alone is considered less effective (around 80% vs. 95%) and is recommended when mifepristone is unavailable. Misoprostol is favored for self-managed abortion due to its low cost, accessibility, and ease of use. However, data on the effectiveness of endorsed misoprostol-alone protocols are limited. This study aims to assess the safety and effectiveness of misoprostol-alone abortion, providing insights into physical experiences and healthcare-seeking behavior, with implications for clinical practice and policy.
The study, which included participants aged 13 and older with no contraindications to medication abortion, focused on those who used misoprostol alone and completed a baseline and two follow-up surveys. The analysis, performed between January 2022 and September 2023, yielded compelling results.
Effectiveness was the primary outcome measured in the study, with complete abortion without procedural intervention as the goal. Safety was the secondary outcome where self-report of experiencing warning signs indicative of a potential complication and by medical treatment. length of bleeding and cramping, time to expulsion, and experience of adverse effects were the other outcomes.
Furthermore, the study delved into the safety of the misoprostol-alone regimen.
Findings:
- Out of the 1352 participants in the study, 637 utilized misoprostol-alone regimens for abortion and were considered in the analysis.
- The majority were from Nigeria (591, 92.8%), with a smaller number from Southeast Asia (45, 7.1%), and just one from Argentina (0.2%).
- Among these, 384 (60.2%) were aged 20-29 years, 317 (49.8%) had pregnancies of less than 7 weeks, and 205 (32.2%) had pregnancies between 7 and less than 9 weeks.
- At the final follow-up, which occurred approximately 22 days after taking the medication (with an interquartile range of 21-26 days), a significant 625 participants (98.1%, 95% confidence interval: 96.7%-98.9%) achieved a complete abortion without requiring any medical intervention.
- A mere 6 participants (0.9%, 95% confidence interval: 0.4%-2.1%) reported potential adverse events.
- Most participants experienced bleeding for a relatively short duration, with a median of 4 days (interquartile range: 3-6 days), and successfully expelled their pregnancies within 24 hours of commencing the abortion process, with a median time of 12 hours (interquartile range: 9-15 hours).
- The common side effects observed included nausea, reported by 335 participants (52.6%), fever in 232 (36.4%), and diarrhea in 181 (28.4%).
In summary, this study's findings suggest that misoprostol alone is a highly effective and safe method for self-managed abortion, challenging preconceived notions about its efficacy. This could have significant implications for reproductive healthcare and access to safe abortion services, offering hope and choice to individuals seeking safe and effective pregnancy termination methods. This information is crucial for healthcare providers and organizations that offer abortion services, as it may inform the development of protocols and guidelines for medication abortion. It can also influence policies and regulations related to access to medication abortion, particularly in regions where abortion services are restricted or inaccessible.
Further reading: Jayaweera R, Egwuatu I, Nmezi S, et al. Medication Abortion Safety and Effectiveness With Misoprostol Alone. JAMA Netw Open. 2023;6(10):e2340042. doi:10.1001/jamanetworkopen.2023.40042
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751